Skip to content

Depression: all studies

Page 278 of 1,036: studies 2,771 to 2,780 of 10,358, newest first. Back to the depression overview

Research

Novel treatment options in depression and psychosis

Neuropsychiatric Disease and Treatment March 1, 2018 Eva Češková, Petr Šilhán

Eva Ceskova, Petr Silhan Department of Psychiatry, University Hospital Ostrava, Ostrava, Czech Republic Abstract: In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing)...

DOI: 10.2147/ndt.s157475 (opens in new tab) Aripiprazole Lurasidone Schizophrenia object-oriented programming Intensive care medicine +1

Glutamatergic Modulators in Depression

Harvard Review of Psychiatry February 21, 2018 Ioline D. Henter, Rafael Teixeira de Sousa, Carlos A. Zarate 94 citations

LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions...

DOI: 10.1097/hrp.0000000000000183 (opens in new tab) Glutamatergic Dextromethorphan Pharmacology Nmda receptor +5

Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Depression

Journal of Affective Disorders February 17, 2018 Mark J. Niciu, Bridget J. Shovestul, Brittany A. Jaso et al. 134 citations

Background Ketamine induces rapid and robust antidepressant effects, and many patients also describe dissociation, which is associated with antidepressant response. This follow-up study investigated whether antidepressant efficacy is uniquely related to dissociative symptom clusters. Methods Treatment-resistant patients with major depressive disorder (MDD) or bipolar disorder (BD) (n=126) drawn...

Mindfulness self-help interventions for symptoms of depression, anxiety and stress: Review and meta-analysis

February 12, 2018 Kristy Martin, Nima Golijani-Moghaddam, R. Das Nair

Background: Mindfulness-based therapy has been found to be an efficacious treatment for a range of mental and physical health conditions. There are increasing efforts to deliver benefits of mindfulness through less intensive/more accessible modalities but whether this efficacy holds in lower-intensity forms is unknown. This paper reviews the effectiveness of mindfulness delivered in a self-help...

Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy.

Journal of Psychiatric Research February 10, 2018 Andrew P. Allen, Maura Naughton, J. Dowling et al. 53 citations

Current first-line antidepressants can take weeks or months to decrease depressive symptoms. Low dose ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows potential for a more rapid antidepressant effect, with efficacy also evident in previously treatment-resistant populations. However, a greater understanding of the physiological mechanisms underlying such effects is required....

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 2, 2018 Simon Reiche, Leo Hermle, Stefan Gutwinski et al. 125 citations

Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently,...

Mindfulness-Based Baduanjin Exercise for Depression and Anxiety in People with Physical or Mental Illnesses: A Systematic Review and Meta-Analysis

International Journal of Environmental Research and Public Health February 1, 2018 L. Zou, Albert Yeung, Xin-Feng Quan et al.

Objectives: we used a quantitative method to systematically synthesize the emerging literature and critically evaluate the effects of Baduanjin on depression and anxiety in people with physical or mental illnesses. Additionally, we determined if the number of total Baduanjin training sessions is associated with decreased anxiety and depression levels. Methods: both English and Chinese databases...

'I had a sort of epiphany!' An exploratory study of group mindfulness-based cognitive therapy for older people with depression.

Aging & Mental Health February 2018 Caroline M Williams, Frances Meeten, Susan Whiting

Mindfulness-based cognitive therapy (MBCT) has been successful in reducing depressive symptoms in people with chronic-recurrent depression. However, the research evaluating the efficacy of this approach, and other innovative treatments for mood disorders, has mainly been with people under 65 years. This paper aims to help redress this imbalance by exploring older people's own reflections of...

DOI: 10.1080/13607863.2016.1247415 (opens in new tab) Full text (opens in new tab) Depression Mindfulness-based cognitive therapy Older people Well-being

Prevention of relapse/recurrence in major depressive disorder with either mindfulness-based cognitive therapy or cognitive therapy.

Journal of Consulting and Clinical Psychology February 2018 Norman A. S. Farb, Adam K. Anderson, Arun Ravindran et al.

Both Mindfulness Based Cognitive Therapy (MBCT) and Cognitive Therapy (CT) enhance self-management of prodromal symptoms associated with depressive relapse, albeit through divergent therapeutic procedures. We evaluated rates of relapse in remitted depressed patients receiving MBCT and CT. Decentering and dysfunctional attitudes were assessed as treatment-specific process markers. Participants...

156 Improvement in Disease Severity in Patients With Treatment-Resistant Depression Following Treatment With Intranasal Esketamine

CNS Spectrums February 1, 2018 Abigail I. Nash, M. Shawi, Jaskaran Singh et al.

Abstract Background Recognizing the importance not only of the clinician’s opinion but also of the patient’s experience and perspective, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) utilized both clinician-reported and patient-reported outcomes in a large-scale multi-step study on antidepressant effectiveness in real-world settings. Both approaches indicate that <17% of Major...